MarketCapExport financials
Cara Therapeutics (CARA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Cara Therapeutics Balance Sheet 2025-2011 | CARA
Brief overview of Cara Therapeutics's financial position
The balance sheet is assessed across five available annual reports spanning 2019 to 2025.
Assets fell from $233 million to $32.1 million. This may reflect either deliberate optimization or a reduction in business scale.
Liability growth of -75.9% exceeded asset growth of -86.2%, increasing reliance on outside funding.
Equity accounts for 65.3% of assets. Against the initial 80.1%, the capital position looks resilient.
Cash exceeds interest-bearing debt, producing net debt of -$20.5 million. The balance sheet therefore carries a net cash position.
Cash accounts for 64.6% of assets versus 7.9% initially. The change indicates the degree of financial flexibility.
The accumulated result is -$110.5 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Conclusion
Cara Therapeutics has a workable but not unconditionally strong balance sheet. Resilience depends on sustained earnings and liability control.
Annual Balance Sheet Cara Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-20.5 M | -31.3 M | -45.7 M | - | -9.78 M | -26.4 M | -14 M | -15.1 M | -9.39 M | -12.1 M | -15.1 M | -52.7 M | -12.4 M | -337 K | -3.34 M |
Long Term Debt |
85 K | 201 K | 6.09 M | - | 1.92 M | 3.67 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
116 K | 103 K | - | 1.92 M | 1.76 M | 1.6 M | 967 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 3.35 M | 16.7 M | 1.72 M | 1.57 M | 585 K | 874 K | 1.14 M | 1.41 M | 1.65 M |
Total Current Liabilities |
11 M | 10.4 M | 25.6 M | 23.5 M | 17.6 M | 18.5 M | 42.9 M | 40.4 M | 8.51 M | 11.5 M | 5.27 M | 3.4 M | - | - | - |
Total Liabilities |
11.1 M | 40.8 M | 68.8 M | 23.5 M | - | - | 46.2 M | 57.2 M | 10.2 M | 13.1 M | 5.85 M | 4.27 M | 6.57 M | 3.1 M | 4.58 M |
Deferred Revenue |
- | - | - | - | - | - | 22.3 M | 26.8 M | - | - | - | 1.45 M | 3.48 M | - | - |
Retained Earnings |
-110 M | -92.2 M | -685 M | -566 M | -481 M | -392 M | -401 M | -294 M | -220 M | -162 M | -105 M | -80.2 M | -62.5 M | -59.4 M | -53.1 M |
Total Assets |
32.1 M | 35.2 M | 126 M | 182 M | 247 M | 271 M | 233 M | 191 M | 97 M | 63.8 M | 111 M | 55.9 M | 18.1 M | 5.54 M | 10.7 M |
Cash and Cash Equivalents |
20.7 M | 31.6 M | 51.8 M | 63.7 M | 13.9 M | 32.1 M | 18.3 M | 15.1 M | 9.39 M | 12.1 M | 15.1 M | 52.7 M | 12.4 M | 1.12 M | - |
Book Value |
20.9 M | -5.63 M | 57.1 M | 159 M | 247 M | 271 M | 187 M | 134 M | 86.8 M | 50.7 M | 105 M | 51.7 M | 11.5 M | 2.44 M | 6.1 M |
Total Shareholders Equity |
20.9 M | -91.1 M | -62.1 M | 159 M | 228 M | 249 M | 187 M | 134 M | 86.8 M | 50.7 M | 105 M | 51.7 M | -54.1 M | -58.1 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Cara Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
54 K | 115 K | 145 K | - | 201 K | - | 7.32 M | 6.82 M | 6.09 M | 6.82 M | - | - | - | 497 K | 983 K | 1.46 M | 1.92 M | 2.37 M | 2.82 M | 3.25 M | 3.67 M | 3.67 M | 3.67 M | 3.67 M | 3.35 M | 3.35 M | 3.35 M | 3.35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
11.3 M | 11.2 M | 10.8 M | 47 M | 40.8 M | 50.6 M | 60.9 M | 60.3 M | 68.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 511 K | 9.77 M | 14.2 M | 22.3 M | 22.3 M | 22.3 M | 22.3 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | - | - | - | - | - | - | - | - | - | - | 89 K | 963 K | 1.45 M | 1.45 M | 1.45 M | 1.45 M | 3.48 M | 3.48 M | 3.48 M | 3.48 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-117 M | -103 M | -97.6 M | -761 M | -92.2 M | -748 M | -735 M | -715 M | -685 M | -652 M | -624 M | -593 M | -566 M | -536 M | -513 M | -509 M | -481 M | -447 M | -446 M | -416 M | -392 M | -392 M | -392 M | -392 M | -401 M | -401 M | -401 M | -401 M | -294 M | -294 M | -294 M | -294 M | -220 M | -220 M | -220 M | -220 M | -162 M | -162 M | -162 M | -162 M | -105 M | -105 M | -105 M | -105 M | -80.2 M | -80.2 M | -80.2 M | -80.2 M | -62.5 M | -62.5 M | -62.5 M | -62.5 M | - | - | - | - | - | - | - | - |
Total Assets |
25.8 M | 39 M | 43.8 M | 38.9 M | 35.2 M | 51.3 M | 72.5 M | 90.1 M | 126 M | 115 M | 134 M | 153 M | 182 M | 214 M | 227 M | 224 M | 247 M | 225 M | 221 M | 250 M | 271 M | 271 M | 271 M | 271 M | 233 M | 233 M | 233 M | 233 M | 191 M | 191 M | 191 M | 191 M | 97 M | 97 M | 97 M | 97 M | 63.8 M | 63.8 M | 63.8 M | 63.8 M | 111 M | 111 M | 111 M | 111 M | 55.9 M | 55.9 M | 55.9 M | 55.9 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
19.9 M | 21.4 M | 20.6 M | 34.2 M | 31.6 M | 9.44 M | 16.1 M | 48.5 M | 51.8 M | 64.8 M | 60.2 M | 47.8 M | 63.7 M | 43.2 M | 47.1 M | 21.8 M | 13.5 M | 23.4 M | 22.7 M | 22.5 M | 32.1 M | 31.7 M | 31.7 M | 31.7 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 9.39 M | 9.39 M | 9.39 M | 9.39 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 52.7 M | 52.7 M | 52.7 M | 52.7 M | 12.4 M | 12.4 M | 12.4 M | 12.4 M | 1.12 M | - | - | - | 4.1 M | - | - | - |
Book Value |
14.5 M | 27.9 M | 32.9 M | -8.07 M | -5.63 M | 707 K | 11.6 M | 29.8 M | 57.1 M | 115 M | 134 M | 153 M | 182 M | 214 M | 227 M | 224 M | 247 M | 225 M | 221 M | 250 M | 271 M | 271 M | 271 M | 271 M | 233 M | 233 M | 233 M | 233 M | 191 M | 191 M | 191 M | 191 M | 97 M | 97 M | 97 M | 97 M | 63.8 M | 63.8 M | 63.8 M | 63.8 M | 111 M | 111 M | 111 M | 111 M | 55.9 M | 55.9 M | 55.9 M | 55.9 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
14.5 M | 27.9 M | 32.9 M | -8.07 M | -91.1 M | -78.5 M | -73.1 M | 29.8 M | 57.1 M | 85.6 M | 109 M | 137 M | 159 M | 185 M | 204 M | 204 M | 228 M | 207 M | 203 M | 230 M | 249 M | 249 M | 249 M | 249 M | 187 M | 187 M | 187 M | 187 M | 134 M | 134 M | 134 M | 134 M | 86.8 M | 86.8 M | 86.8 M | 86.8 M | 50.7 M | 50.7 M | 50.7 M | 50.7 M | 105 M | 105 M | 105 M | 105 M | 51.7 M | 51.7 M | 51.7 M | 51.7 M | -54.1 M | -54.1 M | -54.1 M | -54.1 M | -58.1 M | - | - | - | -52.1 M | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Cara Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
France
USA
Germany
Israel
Britain
China
Belgium
Canada
Singapore
Bermuda
Niderland
Danmark